scholarly journals Assessment of literacy and numeracy skills related to non-steroidal anti-inflammatory drug labels

2019 ◽  
Vol 7 ◽  
pp. 205031211983411 ◽  
Author(s):  
Soo Min Jang ◽  
Ruixin Jiang ◽  
Darren Grabe ◽  
Amy Barton Pai
Keyword(s):  
Primary Care ◽  
Health Literacy ◽  
Vital Sign ◽  
Over The Counter ◽  
Inflammatory Drug ◽  
Scale Range ◽  
Inflammatory Drugs ◽  
Newest Vital Sign ◽  
Anti Inflammatory ◽  
Medication Label

Background: Non-steroidal anti-inflammatory drugs are widely used and have a potential for over-the-counter misuse. Limited health literacy is associated with poor health outcomes. Identification of new strategies to assess literacy and numeracy could be useful in targeting effective education initiatives. Objective: To characterize numeracy and literacy skills related to non-steroidal anti-inflammatory drug labels in primary care patients. Methods: Patients were recruited and consented over an 8-month period after their regular primary care visit. Demographic information was collected and two instruments were administered to assess literacy and numeracy skills: (1) a medication label literacy instrument focused on non-steroidal anti-inflammatory drugs (MedLit-NSAID) and (2) a general healthy literacy-screening tool, the Newest Vital Sign. Two questions on the MedLit-NSAID instrument evaluated understanding of the Food and Drug Administration medication guide for non-steroidal anti-inflammatory drugs and the Food and Drug Administration approved over-the-counter label. Results: A total of 145 patients were enrolled. Mean MedLit-NSAID and Newest Vital Sign scores were 6.8 (scale range 0–8) and 4.2 (scale range 0–6), respectively. Higher education level was associated with higher scores for both tools (p ⩽ 0.05). Total MedLit-NSAID scores on average were higher in females compared with males (6.5 vs 6, p = 0.05). Patients with decreased kidney function (n = 18) had significantly lower MedLit-NSAID scores (p ⩽ 0.05). Test–retest scores were not significantly different for MedLit-NSAID (p = 0.32). The correlation between the tools was 0.54 and internal consistency MedLit-NSAID was 0.61. Conclusion: A medication information focused instrument provided specific information to assess health literacy related to non-steroidal anti-inflammatory drug labels. This information could be utilized to develop patient education initiatives for medication label comprehension.

scholarly journals Evidence-Based Recommendations for Short- and Long-Term Management of Uninvestigated Dyspepsia in Primary Care: An Update of the Canadian Dyspepsia Working Group (CanDys) Clinical Management Tool

2005 ◽  
Vol 19 (5) ◽  
pp. 285-303 ◽  
Author(s):  
Sander JO Veldhuyzen van Zanten ◽  
Marc Bradette ◽  
Naoki Chiba ◽  
David Armstrong ◽  
Alan Barkun ◽  
...  
Keyword(s):  
Primary Care ◽  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Clinical Management ◽  
Management Tool ◽  
Noninvasive Testing ◽  
Ulcer Bleeding ◽  
High Dose ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

The present paper is an update to and extension of the previous systematic review on the primary care management of patients with uninvestigated dyspepsia (UD). The original publication of the clinical management tool focused on the initial four- to eight-week assessment of UD. This update is based on new data from systematic reviews and clinical trials relevant to UD. There is now direct clinical evidence supporting a test-and-treat approach in patients with nondominant heartburn dyspepsia symptoms, and head-to-head comparisons show that use of a proton pump inhibitor is superior to the use of H2-receptor antagonists (H2RAs) in the initial treatment of Helicobacter pylori-negative dyspepsia patients. Cisapride is no longer available as a treatment option and evidence for other prokinetic agents is lacking. In patients with long-standing heartburn-dominant (ie, gastroesophageal reflux disease) and nonheartburn-dominant dyspepsia, a once-in-a-lifetime endoscopy is recommended. Endoscopy should also be considered in patients with new-onset dyspepsia that develops after the age of 50 years. Conventional nonsteroidal anti-inflammatory drugs, acetylsalicylic acid and cyclooxygenase-2-selective inhibitors can all cause dyspepsia. If their use cannot be discontinued, cotherapy with either a proton pump inhibitor, misoprostol or high-dose H2RAs is recommended, although the evidence is based on ulcer data and not dyspepsia data. In patients with nonheartburn-dominant dyspepsia, noninvasive testing for H pylori should be performed and treatment given if positive. When starting nonsteroidal anti-inflammatory drugs for a prolonged course, testing and treatment with H2RAs are advised if patients have a history of previous ulcers or ulcer bleeding.

Reducing pain in certain forms of obstetric pathology: nonsteroidal anti-inflammatory drugs (Сlinical lecture)

2017 ◽  
pp. 9-14
Author(s):  
L. Nazarenko ◽  
Keyword(s):  
Preterm Birth ◽  
Side Effects ◽  
Key Words ◽  
Clinical Efficacy ◽  
Premature Birth ◽  
Pain Syndrome ◽  
Inflammatory Drug ◽  
Threatened Abortion ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

The article discusses the pathogenetic basis for the use of non-steroidal anti-inflammatory drugs (NSPVP) in obstetric practice for the treatment of pain syndrome in women with threatened abortion and pathological preliminary period. Provided with modern views on the mechanisms of analgesic clinical efficacy, side effects NSPVP. Provides information about the place of NSPVP during pregnancy, the risks to the fetus, the positive aspects in the conduct of women at risk of preterm birth, the pathological preliminary period. Key words: nonsteroidal anti-inflammatory drug, pain, premature birth, preliminary period.

Nephrotic Syndrome Associated With Nonsteroidal Anti-inflammatory Drug Use in Two Children

PEDIATRICS ◽  
1990 ◽  
Vol 85 (5) ◽  
pp. 844-847
Author(s):  
Joan Robinson ◽  
Peter Malleson ◽  
David Lirenman ◽  
James Carter
Keyword(s):  
Renal Failure ◽  
Nephrotic Syndrome ◽  
Drug Use ◽  
Renal Disease ◽  
Interstitial Nephritis ◽  
Renal Toxicity ◽  
Plasma Creatinine ◽  
Over The Counter ◽  
Inflammatory Drug ◽  
Anti Inflammatory

Two children with nephrotic syndrome in association with nonsteroidal anti-inflammatory drug (NSAID) use are described, and the literature concerning this association is reviewed. NSAIDs are drugs with the potential for causing significant renal toxicity including the nephrotic syndrome, interstitial nephritis, and renal failure even in children without obvious preceding renal disease. Children prescribed such drugs should be regularly monitored with urinalyses and plasma creatinine estimations. The possibility of toxicity to over-the-counter use of NSAIDs should be remembered.

Patients' Perceptions of Screening for Health Literacy: Reactions to the Newest Vital Sign

2010 ◽  
Vol 15 (4) ◽  
pp. 402-412 ◽  
Author(s):  
Jonathan B. VanGeest ◽  
Verna L. Welch ◽  
Saul J. Weiner
Keyword(s):  
Health Literacy ◽  
Vital Sign ◽  
Newest Vital Sign

scholarly journals Inhibitory Effect of Herbal Remedy PERVIVO and Anti-Inflammatory Drug Sulindac on L-1 Sarcoma Tumor Growth and Tumor Angiogenesis in Balb/c Mice

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
P. Skopiński ◽  
B. J. Bałan ◽  
J. Kocik ◽  
R. Zdanowski ◽  
S. Lewicki ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Tumor Angiogenesis ◽  
Herbal Remedy ◽  
Inhibitory Effect ◽  
Inflammatory Drug ◽  
Anticancer Effects ◽  
Biologic Response ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Anticancer activity of many herbs was observed for hundreds of years. They act as modifiers of biologic response, and their effectiveness may be increased by combining multiple herbal extracts . PERVIVO, traditional digestive herbal remedy, contains some of them, and we previously described its antiangiogenic activity. Numerous studies documented anticancer effects of nonsteroidal anti-inflammatory drugs. We were the first to show that sulindac and its metabolites inhibit angiogenesis. In the present paper the combinedin vivoeffect of multicomponent herbal remedy PERVIVO and nonsteroidal anti-inflammatory drug sulindac on tumor growth, tumor angiogenesis, and tumor volume in Balb/c mice was studied. These effects were checked after grafting cells collected from syngeneic sarcoma L-1 tumors into mice skin. The strongest inhibitory effect was observed in experimental groups treated with PERVIVO and sulindac together. The results of our investigation showed that combined effect of examined drugs may be the best way to get the strongest antiangiogenic and antitumor effect.

scholarly journals Nonsteroidal anti-inflammatory drug use is a risk factor for early Type II endoleak after endovascular abdominal aortic repair

Vascular ◽  
2019 ◽  
Vol 28 (1) ◽  
pp. 53-58
Author(s):  
Yutaka Matsubara ◽  
Kentaro Inoue ◽  
Kazuki Mori ◽  
Masato Morita ◽  
Satoshi Takebayashi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Body Mass Index ◽  
Risk Factor ◽  
Drug Use ◽  
Type Ii ◽  
Type Ii Endoleak ◽  
Inflammatory Drug ◽  
Postoperative Risk ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Objectives Type II endoleak is a problem after endovascular abdominal aneurysm repair. Preoperative risk factors for Type II endoleak include anatomical factors in the lumbar artery and inferior mesenteric artery; however, preventable postoperative risk factors are unknown. Postimplantation syndrome is associated with lower incidence of Type II endoleak. Therefore, we focused on inflammation, and our aim was to investigate nonsteroidal anti-inflammatory drugs as a postoperative risk factor for Type II endoleak. Methods This was a retrospective study of patients with aortic aneurysm who underwent endovascular aneurism repair at the Department of Cardiovascular Surgery, Beppu Medical Center, Oita, Japan, from January 2011 to August 2018. Clinical characteristics were retrieved from patients’ medical records and included age, sex, body mass index, smoking history, comorbidities, treatment devices, medications, and perioperative information, including postimplantation syndrome. Postimplantation syndrome was defined as body temperature >38.5°C with 12,000/dL white blood cells or >10.0 mg/dL C-reactive protein. The primary outcome was the presence or absence of Type II endoleak assessed on the first postoperative enhanced computed tomography scan. Risk factors for Type II endoleak were assessed. Results and conclusions: Of the eligible 84 patients, 20 (24%) had Type II endoleak identified in the first enhanced computed tomographic scans after endovascular aneurism repair. Nonsteroidal anti-inflammatory drug use (odds ratio (OR): 21.2; 95% confidence interval (95% CI): 1.5–308.4; P = 0.026), cerebrovascular disease (OR: 7.27; 95% CI: 1.06–49.99; P = 0.044), and body mass index <22 kg/m2 (OR: 17.3; 95% CI: 2.1–141.8; P = 0.008) were independent risk factors for Type II endoleak after endovascular aneurism repair. Comparing the rate of Type II endoleak among patients who did not receive nonsteroidal anti-inflammatory drugs within 24 h after endovascular aneurism repair, patients who first used nonsteroidal anti-inflammatory drugs 12–24 h after endovascular aneurism repair, and those who received nonsteroidal anti-inflammatory drugs within 12 h after endovascular aneurism repair, we found a significant difference among the groups (4%, 18%, 45%, respectively; P = 0.001). Nonsteroidal anti-inflammatory drug use within 24 h after endovascular aneurism repair is a risk factor for Type II endoleak. We should know nonsteroidal anti-inflammatory drugs within 24 h after endovascular aneurism repair can be a risk of Type II endoleak.

Sign in / Sign up

Export Citation Format

Share Document